Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Zinc  COVID-19 treatment studies for Zinc  C19 studies: Zinc  Zinc   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Ventilation -14% Improvement Relative Risk ICU admission -14% Hospitalization -14% c19zinc.com Kaplan et al. Zinc for COVID-19 RCT LATE TREATMENT Favors zinc Favors control
Kaplan, 30 patient zinc late treatment RCT: 14% higher ventilation [p=1], 14% higher ICU admission [p=1], and 14% higher hospitalization [p=1] https://c19p.org/kaplan
copied to clipboard
Resveratrol and Zinc in the Treatment of Outpatients With COVID-19 – The Reszinate Study - A Phase 1/2 Randomized Clinical Trial Utilizing Home Patient-Obtained Nasal and Saliva Viral Sampling
Kaplan et al., SSRN, 10.2139/ssrn.3934228 (Preprint)
1 Oct 2021    Source   PDF   Share   Tweet
Small RCT of zinc plus resveratrol in COVID-19+ outpatients, showing no significant differences in viral clearance or symptoms. Although the treatment group was older (46.3 vs. 38.5) and had more severe baseline symptoms, they had similar symptomatic recovery by the second week.
risk of mechanical ventilation, 14.3% higher, RR 1.14, p = 1.00, treatment 1 of 14 (7.1%), control 1 of 16 (6.2%).
risk of ICU admission, 14.3% higher, RR 1.14, p = 1.00, treatment 1 of 14 (7.1%), control 1 of 16 (6.2%).
risk of hospitalization, 14.3% higher, RR 1.14, p = 1.00, treatment 1 of 14 (7.1%), control 1 of 16 (6.2%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kaplan et al., 10/1/2021, Randomized Controlled Trial, USA, North America, preprint, 12 authors, study period 21 September, 2020 - 22 January, 2021, average treatment delay 5.9 days, this trial uses multiple treatments in the treatment arm (combined with resveratrol) - results of individual treatments may vary.
All Studies   Meta Analysis
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit